ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2659

Respiratory Symptoms in Patients with Primary SjöGren’s Syndrome – a Case-Control Study

Thomas Mandl1, Peter Olsson1, Roger Hesselstrand2 and Victor Strevens Bolmgren3, 1Dept of Rheumatology, Skane University Hospital Malmö, Lund University, Malmo, Sweden, 2Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, 3Dept of Rheumatology, Skane University Hospital Malmo, Lund University, Malmo, Sweden

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Pulmonary Involvement, Sjogren's syndrome and questionnaires

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Sjögren's Syndrome - Poster II: Clinical Science

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:   To evaluate the amount and impact of respiratory symptoms in patients with primary Sjögren’s syndrome (pSS) and to assess if such symptoms are related to concomitant COPD or ILD.

Methods: Fifty-one consecutive outpatients diagnosed with pSS (median age 61, range 29-82 years, 49 females) and 80 population based controls (median age 61, range 31-80 years, 43 females), denying having been diagnosed with a rheumatological disease, asthma or COPD as well as using bronchodilators and/or inhalation steroids the last 6 months, were included in the study. The pSS patients were evaluated by pulmonary function test as well as CT scans of the lungs. 21 pSS patients fulfilled GOLD criteria for COPD and 9 patients showed radiologic signs of ILD. All subjects also completed a questionnaire on smoking habits from which tobacco consumption could be calculated as well as the St George’s Respiratory Questionnaire (SGRQ) on respiratory symptoms. The controls were then stratified into females and males and a linear regression analysis was performed in which age, body-mass index (BMI) and pack-years were added as co-variates to calculate gender, age, BMI and pack-year standardised values for the SGRQ subscores and total score. From the equations of these analyses, expected values for the SGRQ subscores and total score in the pSS patients were calculated. The expected SGRQ-scores were then compared with the actual SGRQ-scores found in the pSS patients. To compare the SGRQ scores in pSS patients with vs. without COPD we calculated the deviation of SGRQ scores from expected values in each pSS patient and compared the groups. The same calculation was performed to compare pSS patients with and without radiologic signs of ILD.

Results:   pSS patients had significantly increased SGRQ symptom (25.2 (6.6; 40.5) vs. 2.3 (1.4; 3.8); p<0.001), SGRQ activity (39.5 (12.2; 53.6) vs. 12.5 (8.2; 17.5); p<0.001), SGRQ impact (9.9 (0; 23.3) vs. 0.7 (0.5; 1.1); p<0.001) as well as SGRQ total scores (17.4 (7.4; 34.5) vs. 4.6 (3.3; 6.3); p<0.001) in comparison to expected scores based on the results of the population based controls. However, there was no significant difference in the deviation of SGRQ symptom, SGRQ activity, SGRQ impact or SGRQ total scores from expected values in pSS patients with and without COPD or ILD respectively.

Conclusion:   In conclusion we showed that respiratory symptoms were more common amongst pSS patients than in the normal population. Concomitant COPD or ILD did not seem to significantly contribute to these, suggesting that other factors are more important in eliciting such symptoms in pSS patients, of which airway sicca is probably the most important. Since pulmonary involvement in pSS is associated with an increased mortality and respiratory symptoms is a poor marker for pulmonary involvement, we suggest that at least PFT should be performed liberally in all pSS patients regardless of symptoms to enable early detection of pulmonary involvement in these patients.


Disclosure: T. Mandl, None; P. Olsson, None; R. Hesselstrand, None; V. Strevens Bolmgren, None.

To cite this abstract in AMA style:

Mandl T, Olsson P, Hesselstrand R, Strevens Bolmgren V. Respiratory Symptoms in Patients with Primary SjöGren’s Syndrome – a Case-Control Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/respiratory-symptoms-in-patients-with-primary-sjogrens-syndrome-a-case-control-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/respiratory-symptoms-in-patients-with-primary-sjogrens-syndrome-a-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology